MAGELLAN-3 Interim Analysis: High SVR12 Rate Achieved With GLE/PIB Plus SOF and RBV in HCV-Infected Patients With HCV Infection With Previous GLE/PIB Failure
Second Interim Analysis of STREAGER: High Rate of SVR With 8 Weeks of Elbasvir/Grazoprevir in Treatment-Naive Patients With Nonsevere Fibrosis and Genotype 1b HCV Infection
Glecaprevir/Pibrentasvir Achieves High SVR4 Rates in Patients With Genotype 1 HCV Infection and Previous Use of NS5A Inhibitors Plus SOF With or Without RBV in Interim Analysis of Phase IIIb Trial
Addition of RBV Associated With Increased Efficacy of 12 Weeks Sofosbuvir/Velpatasvir in Patients With Genotype 3 HCV Infection and Compensated Cirrhosis
How I Manage HCC Risk Following HCV Cure
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.